Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Ilya Kister; Tim Spelman; Raed Alroughani; Jeannette Lechner-Scott; Pierre Duquette; Francois Grand'Maison; Mark Slee; Alessandra Lugaresi; Michael Barnett; Pierre Grammond; Gerardo Iuliano; Raymond Hupperts; Eugenio Pucci; Maria Trojano; Helmut Butzkueven

doi:10.1136/jnnp-2016-313760

Article info

This article has a correction. Please see:

Correction: Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study - April 01, 2019

Multiple sclerosis

Research paper

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Authors

Ilya Kister Department of Neurology, NYU Multiple Sclerosis Care Center, NYU School of Medicine, New York, New York, USA PubMed articles Google scholar articles
Tim Spelman Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia PubMed articles Google scholar articles
Raed Alroughani Amiri Hospital, Kuwait City, Kuwait PubMed articles Google scholar articles
Jeannette Lechner-Scott John Hunter Hospital, Newcastle, New South Wales, Australia PubMed articles Google scholar articles
Pierre Duquette Hôpital Notre Dame, Montreal, Quebec, Canada PubMed articles Google scholar articles
Francois Grand'Maison Neuro Rive-Sud, Hôpital Charles LeMoyne, Québec, Quebec, Canada PubMed articles Google scholar articles
Mark Slee Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia PubMed articles Google scholar articles
Alessandra Lugaresi Department of Biomedical and NeuroMotor Sciences (DIBINEM), Mater Studiorum - Université di Bologna, Italy and IRCCS Istituto delle Scienze Neurologiche – “UOSI Riabilitazione Sclerosi Multipla” – Bologna, Italy PubMed articles Google scholar articles
Michael Barnett Brain and Mind Research Institute, University of Sydney, Sydney, New South Wales, Australia PubMed articles Google scholar articles
Pierre Grammond Centre de réadaptation déficience physique Chaudière-Appalache, Levis, Quebec, Canada PubMed articles Google scholar articles
Gerardo Iuliano Ospedali Riuniti di Salerno, Salerno, Italy PubMed articles Google scholar articles
Raymond Hupperts Orbis Medical Centre, Sittard-Geleen, The Netherlands PubMed articles Google scholar articles
Eugenio Pucci UOC Neurologia, ASUR Marche, Area Vasta 3, Macerata, Italy PubMed articles Google scholar articles
Maria Trojano Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy PubMed articles Google scholar articles
Helmut Butzkueven Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia PubMed articles Google scholar articles

Correspondence to Dr Ilya Kister, Department of Neurology, NYU Multiple Sclerosis Care Center, NYU School of Medicine, 240 East 38th St, New York, NY 10026, USA; ilya.kister{at}nyumc.org

View Full Text

Citation

Kister I, Spelman T, Alroughani R on behalf of the MSBase Study Group, et al

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Journal of Neurology, Neurosurgery & Psychiatry 2016;87:1133-1137.

Publication history

Received April 12, 2016
Revised May 18, 2016
Accepted May 23, 2016
First published June 13, 2016.

Online issue publication

September 13, 2016

Article Versions

Previous version (13 June 2016).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has a correction. Please see:

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password